Navigation Links
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
Date:1/17/2008

MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Executive Officer of Chiron Corporation (now Novartis).

Dr. Penhoet is currently the President of the Gordon and Betty Moore Foundation, overseeing the philanthropic activities of the Foundation since 2004. Dr. Penhoet has also held the position of Director with Alta Partners, a venture capital partnership investing in life science companies, since 2000. From 1998 to 2002, he served as Dean of the School of Public Health at the University of California, Berkeley. In 1981, Dr. Penhoet co-founded Chiron Corporation and served as its Chief Executive Officer until 1998. Prior to founding Chiron, he was a faculty member of the Biochemistry Department of U.C. Berkeley. Dr. Penhoet also serves as the Vice Chairman of the Independent Citizen's Oversight Committee of the California Institute for Regenerative Medicine which was created by the passage of Proposition 71, also known as the stem cell initiative.

A member of the Institute of Medicine of the National Academies of Sciences and a member of the American Society of Biological Chemists, Dr. Penhoet has co-authored more than 50 scientific articles and papers. In addition to ChemoCentryx, he serves as a Director of Zymogenetics, Scynexis, Metabolex and Renovis, Inc.

Dr. Penhoet earned his A.B. in biology from Stanford University, and his Ph.D. in biochemistry from the University of Washington. He was a post-doctoral fellow at the University of California, San Diego.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, for patients with moderate-to-severe Crohn's disease. For more information, please refer to http://www.chemocentryx.com.

ChemoCentryx believes that certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to (i) that ChemoCentryx anticipates incurring significant losses for the foreseeable future, (ii) dependence on the success of Traficet-EN(TM); (iii) delays in obtaining or a failure to obtain regulatory approval for product candidates, (iv) failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors, (v) the timing, success and cost of preclinical research and clinical studies, (vi) the timing, acceptability and review periods for regulatory filings, (vii) the availability of corporate partners, (viii) uncertainties relating to patent protection and intellectual property rights, (ix) the impact of competitive products and technological changes, (x) competition from other pharmaceutical or biotechnology companies, (xi) the availability of capital and the cost of capital, (xii) other vagaries in the biotechnology industry and (xiii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
2. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
3. LifeVantage Corporation Appoints Industry Veteran David Brown as President & CEO
4. Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
5. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
6. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
7. Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer
8. China Sky One Medical Appoints Independent Auditor
9. Genstar Capital Appoints Mark Hanson to Managing Director
10. Casey Family Programs Appoints New Board Members
11. Casey Family Programs Appoints Dr. America Bracho as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... , ... MD Now Urgent Care opened its newest location on ... marks the urgent care center's eighth location in Miami-Dade county. , The center's address ... The new clinic offers a wide array of services to patients in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... ... Ulster University, Magee Campus in Northern Ireland is hosting The Schools for ... to graduate students exciting new and innovative hope research based on iFred’s “Schools for ... Improvement Service of the Western Health & Social Care Trust (WHSCT) in partnership with ...
(Date:6/23/2017)... ... 23, 2017 , ... Jusino Insurance Services, a locally owned ... greater Chicago metropolitan area, is embarking on a charity drive in conjunction with ... Founded in 1897, Hephzibah Children’s Association is one of the oldest social services ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh ... planning to families and business owners in North Central West Virginia, is embarking ... services to differently abled residents in the region. , The Stepping Stones organization ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/10/2017)... June 9, 2017  Shane K. Burchfield, DPM, is recognized by ... as a Podiatrist in Alabama . ... First Foot Care. He brings over 20 years of experience, as ... and healthcare, to his role. ... PC is pleased to welcome you to his practice," ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology: